Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 6/20 | 0.68 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.68 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | AMY2A | P04746 | 3/20 | 0.50 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.50 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.50 |
| ▸ | CD69 | Q07108 | 1/20 | 0.49 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.47 |
| ▸ | HPSE | Q9Y251 | 2/20 | 0.46 |
| ▸ | CD209 | Q9NNX6 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6816305 | 1.00 | LGALS3 (0.68) | LGALS3LGALS8LGALS4MAPK1AMY2A | |
| SCHEMBL7717427 | 0.97 | LGALS3 (0.64) | LGALS3LGALS8LGALS4MAPK1AMY2A | |
| SCHEMBL6122661 | 0.97 | LGALS3 (0.64) | LGALS3LGALS8LGALS4MAPK1AMY2A | |
| SCHEMBL31694310 | 0.97 | LGALS3 (0.64) | LGALS3LGALS8LGALS4MAPK1AMY2A | |
| SCHEMBL7717429 | 0.97 | LGALS3 (0.64) | LGALS3LGALS8LGALS4MAPK1AMY2A | |
| SCHEMBL6471615 | 0.97 | LGALS3 (0.64) | LGALS3LGALS8LGALS4MAPK1AMY2A | |
| SCHEMBL30970822 | 0.96 | LGALS3 (0.63) | LGALS3LGALS8LGALS4MAPK1AMY2A | |
| SCHEMBL31701570 | 0.96 | LGALS3 (0.63) | LGALS3LGALS8LGALS4MAPK1AMY2A | |
| SCHEMBL13855946 | 0.96 | LGALS3 (0.66) | LGALS3LGALS8LGALS4MAPK1AMY2A | |
| SCHEMBL30185411 | 0.96 | LGALS3 (0.66) | LGALS3LGALS8LGALS4MAPK1AMY2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070042030-A1 | Preparation for the application of agents in mini-droplets | IDEA AG (DE) | 2007-02-22 | — | — | US | disclosed |
| EP-0475160-B2 | Preparation for drug application in minute droplet form | IDEA AG (DE) | 2004-07-14 | — | — | EP | disclosed |
| US-20020142046-A1 | Protein particles for therapeutic and diagnostic use | YEN, RICHARD C.K. | 2002-10-03 | — | — | US | disclosed |
| US-6391343-B1 | PARTICLE COMPRISING FIBRINOGEN BOUND ON SURFACE OF ALBUMIN MATRIX, CAPABLE OF CO-AGGREGATION WITH PLATELETS, AND OF AGGREGATION IN SOLUTION CONTAINING SOLUBLE FIBRINOGEN AT CONCENTRATION NOT CAPABLE OF CLOT FORMATION BY ITSELF | HEMOSPHERE, INC. | 2002-05-21 | — | — | US | disclosed |
| US-6165500-A | Preparation for the application of agents in mini-droplets | IDEA AG (DE) | 2000-12-26 | — | — | US | disclosed |
| US-5945033-A | ALBUMIN, HEMOGLOBIN MIXTURE; STABILITY | HEMOSPHERE, INC. (US) | 1999-08-31 | — | — | US | disclosed |
| US-5725804-A | ALBUMIN PARTICLES STABLE TO RESOLUBILIZATION, POLYOXYETHYLENE GLYCOL, ALCOHOL | HEMOSPHERE, INC. (US) | 1998-03-10 | — | — | US | disclosed |
| EP-0649427-B1 | SEQUENTIAL REMOVAL OF MONOSACCHARIDES FROM THE REDUCING END OF OLIGOSACCHARIDES AND USES THEREOF | BIOMEMBRANE INST (US) | 1998-01-28 | — | — | EP | disclosed |
| US-5616311-A | AQUEOUS ALBUMIN SUSPENSION STABILIZED BY HEMOGLOBIN PARTICLES | HEMOSPHERE, INC. (US) | 1997-04-01 | — | — | US | disclosed |
| EP-0475160-B1 | Preparation for drug application in minute droplet form | IDEA AG (DE) | 1996-02-14 | — | — | EP | disclosed |
| US-5403927-A | Sequential removal of monosaccharides from the reducing end of oligosaccharides and uses thereof | THE BIOMEMBRANE INSTITUTE (US) | 1995-04-04 | — | — | US | disclosed |
| EP-0475160-A1 | Preparation for drug application in minute droplet form | Cevc, Gregor, Prof. Dr. (DE) | 1992-03-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070042030-A1 | Preparation for the application of agents in mini-droplets | FABP4, NPC1L1, LIPA | LGALS3 347/4885LGALS8 437/4885LGALS4 395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.